首頁 > 市場調查報告書 > 製藥

藥物開發

市場調查報告書

商品編碼

1830979

藥物研發服務市場

Drug Discovery Services Market

出版日期: 2025年09月24日 | 出版商:

The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格

簡介目錄

藥物研發服務市場規模預計將從 2024 年的 255.1 億美元增加到 2031 年的 648.9 億美元，2025 年至 2031 年的預估複合年成長率為 14.3%。

市場洞察與分析師觀點：藥物發現是指識別或創造旨在治療疾病和增進人類健康的新藥的過程。該過程包括透過合成、實驗室測試、動物模型評估和人體試驗等各個階段來識別潛在的候選藥物。藥物發現服務提供者提供專業知識和資源來促進藥物發現過程，其中可能包括藥物化學、計算建模、高通量篩選和臨床前測試服務。這些服務通常由合約研究組織 (CRO) 或學術研究機構提供。製藥公司和生技公司利用這些服務來加快藥物發現流程，同時保持效率。

成長動力與挑戰：受各治療領域對創新療法日益成長的需求所推動，藥物研發服務市場正經歷大幅成長。藥物研發過程複雜且漫長，其成功依賴對潛在候選藥物的全面研究以及測試和驗證。因此，製藥公司和研究機構越來越依賴藥物研發服務提供者來支持其藥物開發計畫。這些服務提供者提供標靶識別和驗證、先導化合物最佳化、臨床前研究以及藥物動力學和毒理學測試等重要服務。此外，生物技術和製藥公司正致力於開發針對個別患者特定基因和分子特徵的標靶治療方案，從而促進更個人化的醫療保健。精準醫療和個人化治療的日益普及進一步推動了對藥物研發服務的需求。

製藥公司不斷增加的研發投入，加上高通量篩選、計算建模和人工智慧等先進技術的普及，也為藥物研發服務市場帶來了利多。這些技術促進了更有效率、更有效的藥物研發流程，從而提高了新藥的上市成功率。新藥的研發成本高昂，通常需要在研發和臨床試驗方面投入大量資金。根據《基因工程與生物技術》雜誌的研究，去年全球排名前20的生物製藥公司新藥研發平均成本上漲了15%（2.98億美元），達到近23億美元。

臨床試驗後期候選藥物的高失敗率進一步推高了藥物開發的整體成本。因此，製藥和生物技術公司日益尋求經濟高效的藥物發現服務，這促使服務提供者在維持高品質標準的同時提供具有競爭力的價格。藥物分子的高昂成本也影響了患者對新療法的可負擔性，尤其是在罕見疾病或利基治療領域，這對藥物開發商和醫療保健系統在確保創新療法的可及性方面都構成了重大挑戰。

策略洞察報告細分和範圍：藥物發現服務市場根據流程、類型、分子類型、治療領域和最終用戶進行分類。就流程而言，市場分為目標選擇和驗證、先導化合物識別和其他（例如檢測開發和篩選）。按類型分類，藥物發現服務市場分為生物服務、藥物化學、藥物代謝和藥物動力學。就分子類型而言，市場分為生物製劑和小分子。依治療領域，市場細分為心血管疾病、腫瘤學、神經科、糖尿病、呼吸系統疾病等。按最終用戶分類，市場分為製藥和生物技術公司、學術機構和其他。從地理上看，藥物發現服務市場分為北美（美國、加拿大和墨西哥）、歐洲（英國、德國、法國、義大利、西班牙和歐洲其他地區）、亞太地區（中國、日本、印度、韓國、澳洲和亞太其他地區）、中東和非洲（阿拉伯聯合大公國、沙烏地阿拉伯、南非和中東和非洲其他地區）以及南美洲和中美洲（巴西、阿根廷和南美洲其他地區）。

細分分析：依分子類型分類，小分子藥物在藥物研發服務市場中佔據較大收入佔有率。小分子藥物市場的成長得益於其研究簡單、特性明確且易於表徵。

2022年，按類型分類，藥物化學領域佔據了藥物發現服務市場的最大佔有率。藥物化學廣泛應用於藥物發現的各個方面，從候選藥物的遞送到臨床前研究。

就治療領域而言，腫瘤學領域在2022年引領了藥物研發服務市場。該領域的成長與全球在癌症相關藥物研發方面不斷增加的投入息息相關。由於一般人群中各種癌症的發生率不斷上升，腫瘤學市場正在不斷擴張。國際癌症研究機構估計，2020年全球約有1,000萬人死於癌症，新增癌症病例1,930萬例。預計2020年至2040年，全球新增癌症病例將成長47%，到2040年全球新增癌症病例預計將達到2,840萬例。

藥物發現服務市場報告範圍：區域分析：從地理上看，藥物發現服務市場主要分佈在北美、歐洲、亞太地區、中東和非洲以及南美和中美。北美是全球市場成長的最大貢獻者，這得益於藥物開發公司的投資、美國政府的大量撥款、大型藥物開發公司的強大影響力、完善的醫療基礎設施以及慢性病發病率的上升。

美國癌症協會發布的《2022年癌症事實與數據》估計，到2022年底，美國將新增約1,918,030例癌症病例，並有609,360例癌症相關死亡病例。鑑於該地區癌症發生率高，預計未來幾年美國抗癌藥物創新研究活動將蓬勃發展。 2022年9月，CytoReason與輝瑞達成多年期合作，輝瑞將運用CytoReason的人工智慧技術進行藥物開發。美國主要公司將人工智慧技術融入藥物研發領域，預計將推動藥物研發服務市場的成長。

預計2022年至2030年，亞太地區藥物研發服務市場的複合年成長率將達到最高。該地區的成長得益於中國、印度、日本和韓國等國家對研發活動的投入不斷增加，這些國家正逐漸成為製藥和生物技術的重要樞紐。此外，亞太地區擁有大量高技能的研究人員和科學家，且營運成本低於西方國家，使其成為藥物研發服務外包的理想目的地。慢性病盛行率的上升以及對創新藥物以滿足未滿足醫療需求的需求，進一步推動了該地區藥物研發服務市場的成長。

競爭格局和主要公司：藥物研發服務市場的主要參與者包括安捷倫科技、Ubiquigent、雅培實驗室、Advinus Therapeutics、Albany Molecular Research Inc.、Aurigene、拜耳公司、阿斯利康公司、Charles River Laboratories International、Covance 和 ChemBridge Corporation。這些公司致力於擴展其服務範圍，以滿足日益成長的全球需求。其國際影響力使其能夠滿足廣泛的客戶群，從而提升其市場佔有率。

北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 德國
- 法國
- 義大利
- 西班牙
- 英國
- 歐洲其他地區
亞太
- 澳洲
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
南美洲和中美洲
- 巴西
- 阿根廷
- 南美洲和中美洲其他地區

第13章：新冠疫情前後的影響

第 14 章：產業格局

併購
協議、合作、合資企業
新產品發布
擴張和其他策略發展

第 15 章：競爭格局

關鍵參與者的熱圖分析
公司定位與集中度

第 16 章：藥物研發服務市場 - 主要公司簡介

Abbott Laboratories
Agilent Technologies
Ubiquigent
Albany Molecular Research Inc.
AstraZeneca PLC
Aurigene
Bayer AG
Charles River Laboratories International
ChemBridge Corporation
Covance

第 17 章：附錄

簡介目錄

Product Code: TIPRE00003410

The drug discovery services market size is expected to increase from US$ 25.51 billion in 2024 to US$ 64.89 billion by 2031, with a projected CAGR of 14.3% from 2025 to 2031.

Market Insights and Analyst View:Drug discovery refers to the process of identifying or creating new medications aimed at treating diseases and enhancing human health. This process encompasses the identification of potential drug candidates through various stages, including synthesis, laboratory testing, animal model evaluation, and human trials. Providers of drug discovery services offer specialized knowledge and resources to facilitate the drug discovery process, which may include medicinal chemistry, computational modeling, high-throughput screening, and preclinical testing services. These services are typically offered by contract research organizations (CROs) or academic research institutions. Pharmaceutical companies and biotechnology firms utilize these services to expedite drug discovery processes while maintaining efficiency.

Growth Drivers and Challenges:The drug discovery services market is witnessing substantial growth driven by the increasing demand for innovative therapies across various therapeutic areas. The drug discovery process is intricate and lengthy, with its success relying on comprehensive research into potential drug candidates, along with their testing and validation. Consequently, pharmaceutical companies and research institutions are increasingly depending on drug discovery service providers to bolster their drug development initiatives. These providers offer essential services such as target identification and validation, lead optimization, preclinical studies, and pharmacokinetic and toxicology testing. Additionally, biotechnology and pharmaceutical companies are striving to create targeted treatments that cater to the specific genetic and molecular profiles of individual patients, promoting a more personalized healthcare approach. This growing emphasis on precision medicine and personalized therapies further drives the demand for drug discovery services.

Rising R&D investments from pharmaceutical companies, coupled with the availability of advanced technologies like high-throughput screening, computational modeling, and artificial intelligence, are also advantageous for the drug discovery services market. These technologies facilitate more efficient and effective drug discovery processes, resulting in a higher success rate for new drug introductions. The process of discovering and developing new drugs is costly, often necessitating significant investments in research, development, and clinical trials. According to a study by Genetic Engineering & Biotechnology, the average cost of developing new medicines among the top 20 global biopharmaceuticals rose by 15% ($298 million) to nearly $2.3 billion last year.

The high failure rate of drug candidates in the later phases of clinical trials further escalates the overall cost of drug development. As a result, pharmaceutical and biotechnology companies are increasingly seeking cost-effective drug discovery services, prompting service providers to offer competitive pricing while upholding high-quality standards. The substantial cost of drug molecules also affects the affordability of new therapies for patients, particularly in the context of rare diseases or niche therapeutic areas, presenting a significant challenge for both drug developers and healthcare systems in ensuring access to innovative treatments.

Strategic Insights

Report Segmentation and Scope:The drug discovery services market is categorized based on process, type, molecule type, therapeutic area, and end user. In terms of process, the market is divided into target selection and validation, hit to lead identification, and others (such as assay development and screening). By type, the drug discovery services market is segmented into biology services, medicinal chemistry, drug metabolism, and pharmacokinetics. Regarding molecule type, the market is classified into biologics and small molecules. Based on therapeutic areas, the market is segmented into cardiovascular diseases, oncology, neurology, diabetes, respiratory diseases, and others. By end user, the market is divided into pharmaceutical and biotechnology companies, academic institutions, and others. Geographically, the drug discovery services market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Segmental Analysis:The small molecules segment accounted for a larger revenue share of the drug discovery services market, based on molecule type. The growth of the small molecules market is attributed to their simplicity in study, well-defined characteristics, and ease of characterization.

In 2022, the medicinal chemistry segment held the largest share of the drug discovery services market by type. Medicinal chemistry is extensively utilized in various aspects of drug discovery, from candidate delivery to preclinical studies.

In terms of therapeutic area, the oncology segment led the drug discovery services market in 2022. The growth of this segment is linked to the increasing global efforts in cancer-related drug discovery. The oncology market is expanding due to the rising incidence of various cancers among the general population. The International Agency for Research on Cancer estimated approximately 10 million cancer-related deaths and 19.3 million new cancer cases in 2020. The global number of new cancer cases is projected to rise by 47% from 2020 to 2040, leading to an estimated 28.4 million new cancer cases worldwide by 2040.

Drug Discovery Services Market Report Scope

Regional Analysis:Geographically, the drug discovery services market is primarily segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America is the largest contributor to the growth of the global market, driven by investments from drug development companies, substantial grants from the US government, a strong presence of major drug development firms, a well-established healthcare infrastructure, and an increase in chronic disease incidences.

The American Cancer Society's "Cancer Facts & Figures 2022" estimated around 1,918,030 new cancer cases and 609,360 cancer-related deaths in the US by the end of 2022. Given the high cancer rates in this region, research activities aimed at innovating cancer drugs are expected to thrive in the US in the coming years. In September 2022, CytoReason and Pfizer entered into a multi-year collaboration, allowing Pfizer to utilize CytoReason's artificial intelligence technology for drug development. The integration of AI technology in drug discovery by major US companies is anticipated to drive the growth of the drug discovery services market.

Asia Pacific is projected to exhibit the highest CAGR in the drug discovery services market from 2022 to 2030. The growth in this region is attributed to increasing investments in research and development activities in countries like China, India, Japan, and South Korea, which are emerging as key hubs for pharmaceuticals and biotechnology. Additionally, the availability of a large pool of skilled researchers and scientists, along with lower operational costs compared to Western countries, makes Asia Pacific an appealing destination for outsourcing drug discovery services. The rising prevalence of chronic diseases and the demand for innovative medications to meet unmet medical needs are further propelling the growth of the drug discovery services market in the region.

Competitive Landscape and Key Companies:Key players in the drug discovery services market include Agilent Technologies, Ubiquigent, Abbott Laboratories Inc., Advinus Therapeutics, Albany Molecular Research Inc., Aurigene, Bayer AG, AstraZeneca PLC, Charles River Laboratories International, Covance, and ChemBridge Corporation. These companies are focused on expanding their service offerings to meet the growing global demand. Their international presence enables them to cater to a broad customer base, thereby enhancing their market share.

1. Introduction

1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness Analysis

3. Research Methodology

4. Drug Discovery Services Market Landscape

4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain

5. Drug Discovery Services Market - Key Market Dynamics

5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints

6. Drug Discovery Services Market - Global Market Analysis

6.1 Drug Discovery Services - Global Market Overview
6.2 Drug Discovery Services - Global Market and Forecast to 2030

7. Drug Discovery Services Market - Revenue Analysis (USD Million) - By Process, 2020-2030

7.1 Overview
7.2 Target Selection and Validation
7.3 Hit To Lead Identification
7.4 Others

8. Drug Discovery Services Market - Revenue Analysis (USD Million) - By Type, 2020-2030

8.1 Overview
8.2 Biology Services
8.3 Medicinal Chemistry
8.4 Drug Metabolism and Pharmacokinetics

9. Drug Discovery Services Market - Revenue Analysis (USD Million) - By Molecule Type, 2020-2030

9.1 Overview
9.2 Biologics
9.3 Small Molecules

10. Drug Discovery Services Market - Revenue Analysis (USD Million) - By Therapeutic Area, 2020-2030

10.1 Overview
10.2 Cardiovascular Diseases
10.3 Oncology
10.4 Neurology
10.5 Diabetes
10.6 Respiratory Diseases
10.7 Others

11. Drug Discovery Services Market - Revenue Analysis (USD Million) - By End User, 2020-2030

11.1 Overview
11.2 Pharmaceutical and Biotechnology Companies
11.3 Academic Institutes
11.4 Others

12. Drug Discovery Services Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

12.1 North America
- 12.1.1 North America Drug Discovery Services Market Overview
- 12.1.2 North America Drug Discovery Services Market Revenue and Forecasts to 2030
- 12.1.3 North America Drug Discovery Services Market Revenue and Forecasts and Analysis - By Process
- 12.1.4 North America Drug Discovery Services Market Revenue and Forecasts and Analysis - By Type
- 12.1.5 North America Drug Discovery Services Market Revenue and Forecasts and Analysis - By Molecule Type
- 12.1.6 North America Drug Discovery Services Market Revenue and Forecasts and Analysis - By Therapeutic Area
- 12.1.7 North America Drug Discovery Services Market Revenue and Forecasts and Analysis - By End User
- 12.1.8 North America Drug Discovery Services Market Revenue and Forecasts and Analysis - By Countries
  - 12.1.8.1 United States Drug Discovery Services Market
    - 12.1.8.1.1 United States Drug Discovery Services Market, by Process
    - 12.1.8.1.2 United States Drug Discovery Services Market, by Type
    - 12.1.8.1.3 United States Drug Discovery Services Market, by Molecule Type
    - 12.1.8.1.4 United States Drug Discovery Services Market, by Therapeutic Area
    - 12.1.8.1.5 United States Drug Discovery Services Market, by End User
  - 12.1.8.2 Canada Drug Discovery Services Market
    - 12.1.8.2.1 Canada Drug Discovery Services Market, by Process
    - 12.1.8.2.2 Canada Drug Discovery Services Market, by Type
    - 12.1.8.2.3 Canada Drug Discovery Services Market, by Molecule Type
    - 12.1.8.2.4 Canada Drug Discovery Services Market, by Therapeutic Area
    - 12.1.8.2.5 Canada Drug Discovery Services Market, by End User
  - 12.1.8.3 Mexico Drug Discovery Services Market
    - 12.1.8.3.1 Mexico Drug Discovery Services Market, by Process
    - 12.1.8.3.2 Mexico Drug Discovery Services Market, by Type
    - 12.1.8.3.3 Mexico Drug Discovery Services Market, by Molecule Type
    - 12.1.8.3.4 Mexico Drug Discovery Services Market, by Therapeutic Area
    - 12.1.8.3.5 Mexico Drug Discovery Services Market, by End User
12.2 Europe
- 12.2.1 Germany
- 12.2.2 France
- 12.2.3 Italy
- 12.2.4 Spain
- 12.2.5 United Kingdom
- 12.2.6 Rest of Europe
12.3 Asia-Pacific
- 12.3.1 Australia
- 12.3.2 China
- 12.3.3 India
- 12.3.4 Japan
- 12.3.5 South Korea
- 12.3.6 Rest of Asia-Pacific
12.4 Middle East and Africa
- 12.4.1 South Africa
- 12.4.2 Saudi Arabia
- 12.4.3 U.A.E
- 12.4.4 Rest of Middle East and Africa
12.5 South and Central America
- 12.5.1 Brazil
- 12.5.2 Argentina
- 12.5.3 Rest of South and Central America

13. Pre and Post Covid-19 Impact

14. Industry Landscape

14.1 Mergers and Acquisitions
14.2 Agreements, Collaborations, Joint Ventures
14.3 New Product Launches
14.4 Expansions and Other Strategic Developments

15. Competitive Landscape

15.1 Heat Map Analysis by Key Players
15.2 Company Positioning and Concentration

16. Drug Discovery Services Market - Key Company Profiles

16.1 Abbott Laboratories
- 16.1.1 Key Facts
- 16.1.2 Business Description
- 16.1.3 Products and Services
- 16.1.4 Financial Overview
- 16.1.5 SWOT Analysis
- 16.1.6 Key Developments
16.2 Agilent Technologies
16.3 Ubiquigent
16.4 Albany Molecular Research Inc.
16.5 AstraZeneca PLC
16.6 Aurigene
16.7 Bayer AG
16.8 Charles River Laboratories International
16.9 ChemBridge Corporation
16.10 Covance